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Type 2 diabetes mellitus (T2DM) is a worldwide heath problem that is characterized by insulin resistance and the eventual
loss of β cell function. As recent studies have shown that loss of ribosomal protein (RP) S6 kinase 1 (S6K1) increases
systemic insulin sensitivity, S6K1 inhibitors are being pursued as potential agents for improving insulin resistance. Here
we found that S6K1 deficiency in mice also leads to decreased β cell growth, intrauterine growth restriction (IUGR), and
impaired placental development. IUGR is a common complication of human pregnancy that limits the supply of oxygen
and nutrients to the developing fetus, leading to diminished embryonic β cell growth and the onset of T2DM later in life.
However, restoration of placental development and the rescue of IUGR by tetraploid embryo complementation did not
restore β cell size or insulin levels in S6K1–/– embryos, suggesting that loss of S6K1 leads to an intrinsic β cell lesion.
Consistent with this hypothesis, reexpression of S6K1 in β cells of S6K1–/– mice restored embryonic β cell size, insulin
levels, glucose tolerance, and RPS6 phosphorylation, without rescuing IUGR. Together, these data suggest that a
nutrient-mediated reduction in intrinsic β cell S6K1 signaling, rather than IUGR, during fetal development may underlie
reduced β cell growth and eventual development of T2DM later in life.
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Introduction
The common hallmark of frank type 2 diabetes mellitus (T2DM) 
is insulin resistance, which is initially compensated for by an 
increase in β cell mass and insulin production before eventually 
yielding to β cell failure (1). The number of diabetics worldwide 
is presently 347 million (2), with WHO projecting that diabetes 
will be become the 7th leading cause of death by 2030 (3), under-
scoring the need for novel therapies (4). Ribosomal protein (RP) 
S6 kinase 1 (S6K1), a downstream effector of the mTOR Complex 
1 (mTORC1) signaling pathway (5), has emerged as a potential 
drug target in the treatment of T2DM (6–8). In earlier studies, we 
demonstrated that mice deficient for S6K1 are resistant to high-fat 
diet–induced (HFD-induced) obesity due to increased lipolysis (9) 
and a lesion in adipogenesis, which we subsequently traced to an 
impairment in the ability of stem cells to commit to the adipocytic 
lineage (10). Consistent with a reduction in adiposity, as com-
pared with WT mice, S6K1–/– mice maintained on a HFD remain 
insulin sensitive, despite increased glycemia (9). Increased insulin 
sensitivity may also result from the reduced circulating insulin lev-
els in S6K1–/– mice, as well as the loss of a negative feedback loop 
mediated by S6K1 site-specific phosphorylation to elements of the 
insulin receptor pathway, particularly insulin receptor substrates 
1/2 (IRS1/2) (5, 9). In the latter case, phosphorylation of IRS1/2 
disrupts its interactions with the insulin receptor and the class 1 
PI3K (11, 12), which is hypothesized to suppress glucose uptake in 
muscle and adipose (5, 9). Consistent with these findings, liver- 
specific depletion of S6K1 has been recently shown to protect 
against HFD-induced hepatic steatosis and systemic whole-body 
insulin resistance, the latter being associated with reduced insulin 
levels and loss of the negative feedback loop in muscle and fat (13).
Despite the finding that depletion or loss of S6K1 leads to an 
increase in insulin sensitivity, there is a concern about the poten-
tial efficacy of S6K1 inhibitors for the treatment of T2DM. As 
noted above, this stems from the fact that S6K1-deficient mice are 
hypoinsulinemic, a phenotype which we found was not associated 
with the transcription, synthesis, degradation, or intrinsic secre-
tion of insulin, but with diminished β cell size (9, 14). It is known 
that a decrease in β cell size has a proportionally larger negative 
effect on insulin secretion independent of secretory potential (15). 
Consistent with a role for S6K1 in this response, subsequent stud-
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small gestational–age fetuses and newborns 
(21). The fetal oxygen and nutrient supply is 
normally actively transported from the mother 
to the placental trophoblasts, which develop 
during the early stages of pregnancy and are 
the first cells of the fertilized egg to differenti-
ate. mTORC1, an upstream kinase required for 
S6K1 activation, is critical for the trophoblast’s 
development and function (22). Of note, S6K1 
activity is markedly reduced in human placen-
tas associated with restricted fetal growth (23). 
These findings and the observation that acute 
inhibition of S6K1 by rapamycin in β cells has 
no effect on glucose-stimulated insulin secre-
tion (24) are consistent with IUGR, rather than 
an intrinsic β cell function, being responsible 
for the reduced body mass, hypoinsulinemia, 
and the β cell size deficit displayed by S6K1 
deficient mice at birth (14, 17).
Given the importance of S6K1 as a potential 
therapeutic target in insulin resistance (8) and 
recent data suggesting that fetal β cell impair-
ment, rather than being a consequence, is instead 
a cause of IUGR (25), we set out to trace the basis 
of the reduced β cell size and hypoinsulinemia 
observed in adult S6K1–/– mice. To address this 
question, we first determined β cell size and 
insulin content in S6K1–/– mouse embryos. Next, 
we asked which stage of S6K1–/– mouse embry-
onic development was affected and whether the 
developmental effects could be accounted for 
by reduced β cell size. Finally, employing 2 dis-
tinct genetic paradigms, we determined whether 
the effects on β cell size and hypoinsulinemia 
observed in adult S6K1–/– mice were due to IUGR 
or were intrinsic to β cells.
Results
β Cells from S6K1–/– embryos exhibit reduced cell 
size and insulin content. As limited intrauterine 
nutrient availability has been associated with 
impaired pancreatic β cell development (26, 
27), we asked whether β cells are affected in 
S6K1–/– mice during embryogenesis. Examination of H&E-stained 
pancreata at E16.5 revealed clusters of endocrine cells in the pan-
creatic interstitium (Figure 1A). In S6K1–/– embryos, we observed 
a higher density of nuclei in the endocrine cell clusters, as com-
pared with WT embryos (Figure 1A). The same β cell phenotype 
was observed in S6K1–/– mice obtained either from heterozygous or 
homozygous parental crosses. Analysis of tissue sections of β cells, 
immunostained for the membrane-associated GLUT2 transporter, 
confirmed that S6K1–/– β cells were smaller than those from WT 
embryos (Figure 1B). Given that S6K1 deficiency affects apoptosis 
(28, 29), we examined apoptotic β cells by costaining for cleaved 
caspase-3 and insulin, together with DAPI, to observe nuclei. The 
result revealed significant levels of cleaved caspase-3 staining in 
S6K1–/– β cells (WT 0%, S6K1–/– 17%, P < 0.008) and surrounding 
ies showed that targeted β cell expression of a constitutively active 
S6K1 cDNA leads to an increase in both β cell size and insulin secre-
tion (16). However, at birth, S6K1–/– mice are also reduced in body 
size (17), a phenotype that defines intrauterine growth restriction 
(IUGR). IUGR is a risk factor for T2DM in adult life and is asso-
ciated with reduced β cell function (18). IUGR affects over 5% of 
pregnancies, with the number of incidences progressively increas-
ing over the past decade (19). IUGR is largely attributed to an 
insufficient oxygen and nutrient supply by the placenta, such that 
developing tissues and organs of the embryo fail to grow to their 
normal size (20). IUGR fetuses have reduced circulating insulin 
levels, impaired β cell function, and in more severe cases, reduced 
β cell mass (18). The impairment to β cell function is thought to 
be responsible for the increased insulin sensitivity observed in 
Figure 1. Diminished pancreatic β cell size and number in S6K1–/– embryos. (A–D) Pancreas 
sections from WT or S6K1–/– embryos at E16.5: (A) histology, by H&E staining; (B) GLUT2 glucose 
transporter, by immunofluorescence (IF) staining; (C) cleaved caspase-3 (red), insulin (green) by 
IF staining and DAPI (blue) staining; and (D) insulin (red) and glucagon (green), by IF staining. (E) 
β cell number in embryonic pancreata (n = 3 per genotype). (F) β cell size in embryonic pancreata 
from 45–52 determinations in WT embryos and 29–44 determinations in S6K1–/– embryos (n = 3 
per genotype; β cell surface: WT, 95.60 ± 2.69 μm2; S6K1–/–, 69.54 ± 1.5 μm2). (G) Reduced insulin 
content, normalized for body weight, in embryonic pancreata (n = 6–9 per genotype). Scale bars: 
25 μm. In E–G, values are given as mean ± SEM. *P < 0.05, **P < 0.01 vs. WT, unpaired t test.
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reaching only 80% of that of WT embryos (Figure 2A). Previously, 
we demonstrated that flies deficient for the Drosophila orthologue 
of S6K1, dS6K, were not only severely reduced in size, but were 
strongly delayed in development (30). To establish whether IUGR 
was associated with a developmental delay in S6K1–/– embryos, 
we analyzed cartilage formation and bone ossification during 
development. We found that IUGR was accompanied by a devel-
opmental delay — as measured at E16.5 by reduced staining for 
cartilage and bone, with alcian blue and alizarin red, respectively 
— as well as by deferred chondrocyte hypertrophy in the cervical 
vertebrae (Figure 2B). By E17, the differences in bone ossification 
and bone growth were less striking but not resolved (Supplemental 
Figure 1; supplemental material available online with this article; 
doi:10.1172/JCI77030DS1). As with the β cell growth, the effects 
on skeletal development were equivalent in S6K1–/– mice obtained 
either from maternal heterozygous or null S6K1 crosses. To deter-
mine if the delay in development was elicited at an earlier stage, 
we analyzed whole embryos by scanning electron microscopy at 
tissue, whereas none was detected in WT tissue sections (Figure 
1C). Morphometric analysis of pancreatic tissue sections costained 
for insulin and glucagon (Figure 1D) revealed a 25% and a 27% 
reduction in β cell number and size, respectively, in S6K1–/– versus 
WT embryos (Figure 1, E and F). However, there was no significant 
difference in the size or number of glucagon-positive α cells, sug-
gesting a selective effect on β cells (Figure 1, E and F). The decrease 
in β cell size was consistent with a 50% reduction in the insulin 
content of S6K1–/– versus WT embryos, normalized to embryonic 
body weight (Figure 1G). The reduction in insulin content and β cell 
size during embryonic development persists throughout adult life, 
suggesting that the phenotype observed in adult S6K1–/– mice arises 
from impaired embryonic pancreatic β cell growth.
S6K1–/– mice are developmentally retarded and display IUGR. To 
determine if the reduction in β cell number and size observed in 
S6K1–/– embryos was associated with IUGR, we examined embry-
onic body weights from E11.5–E18.5. The results show that S6K1–/– 
embryos displayed IUGR as early as E12.5, with their weight 
Figure 2. S6K1–/– embryos are developmentally retarded and display IUGR. (A) Weight of WT and S6K1–/– embryos at the indicated gestational ages. 
A total of 234 WT and 223 S6K1–/– embryos was analyzed. n = 25–33 at each time point, for both genotypes. (B) Bone development in WT and S6K1–/– 
embryos. Top panel: Lateral view of skeleton at E16.5 analyzed for ossification, using alcian blue (cartilage) and alizarine red (bone). Arrows indicate 
ossification in the frontal bone of the cranium; in the fibula and tibia bone on the hind limb of WT embryo, the corresponding areas on the S6K1–/– embryo 
are still cartilaginous. Bottom panels: Hypertrophied chondrocytes in cervical vertebrae from WT (left) but not in S6K1–/– (right) at E14.5. (C) Lateral view of 
E9.5 embryos (asterisk indicates somite) by scanning electron microscopy (left) and number of somites (right) (n = 12 per genotype). Note the open otic pit 
(open arrow) and the absence of a limb bud (filled arrow) in the S6K1–/– embryo. (D) Preimplantation development–stage analysis using 106 eggs from 7 WT 
mice and 45 eggs from 4 S6K1–/– mice. Scale bar: 25 μm. In A, C, and D, values are given as mean ± SEM. *P < 0.05 vs. WT, unpaired t test.
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both trophoblast and mesodermal origin that undergo branching 
morphogenesis to produce the large surface area required for the 
placental exchange of nutrients and gases (32). Morphological 
analysis revealed that S6K1–/– placentas weighed 12%–16% less 
than those of WT mice from E11.5–E13.5 (Figure 3A), whereas, the 
S6K1–/– embryos weighed 25%–36% less than those of WT mice 
during this same stage of development (Figure 2A). It is well doc-
umented that a reduction in placental size can directly impact the 
size of the embryo, due the placenta’s ability to transfer nutrients 
from the mother to the fetus (33). These observations suggested 
that the negative effect of the loss of S6K1 on embryonic growth 
may be attributed to impaired placental development (see below). 
Histological examination of placentas from S6K1–/–, S6K1+/–, and 
WT embryos showed normal morphology of the giant cells that 
form a layer between the maternal decidual tissue and the embry-
onic labyrinth (Supplemental Figure 2, A–C). However, compared 
with WT and S6K+/– placentas, the spongiotrophoblast layer of 
S6K1–/– placentas was reduced in size, as assessed by H&E stain-
ing (Figure 3, B and C, and Supplemental Figure 2, A–C, G, and 
H). An intact spongiotrophoblast layer is required for normal 
development of the labyrinth, which secretes vascular endothelial 
growth factor to induce normal blood vessel function (32). More-
over, H&E staining revealed that the S6K1–/– placentas appeared to 
have a slightly larger–sized labyrinth layer but displayed a sharp 
reduction in embryonic and maternal blood vessel association, 
with the fetal blood vessels highly dilated (Figure 3D). This result 
was confirmed by immunostaining of platelet/endothelial cell 
adhesion molecule-1 (PECAM-1) (Figure 3E and Supplemental 
Figure 2, D–F), again indicating a decreased vascular capacity 
of the labyrinth layer in S6K1–/– placentas. The decrease in blood 
vessel intermingling suggested restricted nutrient and oxygen 
exchange between the mother and the developing embryo, which 
could directly impact the size of the fetus (33). In addition, S6K1–/– 
placentas displayed improperly positioned, trophoblast-specific, 
Tpbp-expressing cells in the labyrinth region at E19.5 (Supplemen-
tal Figure 2, I and J). The fact that the S6K1–/– placental phenotypes 
observed were alike, regardless of the parental genotype, is con-
sistent with the trophoblast playing a dominant role in the devel-
opment of the placenta (33). Taken together, these results suggest 
that impaired placental development, as depicted by the defects in 
the spongiotrophoblast and labyrinthine layers, may be responsi-
ble for IUGR of S6K1–/– mice.
Rescue of IUGR, but not reduced β cell size, by tetraploid WT pla-
centa. Given the importance of the placenta in pancreatic β cell 
growth and development (27, 34), we reasoned that the placental 
E9.5. We found that S6K1–/– embryos had a reduced number of 
somites and a delay in otic pit closure, as well as the appearance 
of limb buds, indicating an approximate half-day delay in devel-
opment (Figure 2C). Finally, we assessed preimplantation blas-
tocysts to determine whether IUGR observed in S6K1–/– embryos 
reflected an intrinsic defect in embryonic development. This anal-
ysis revealed no visible anomalies in the S6K1–/– preimplantation 
blastocysts, with 60% of the eggs of both genotypes developing to 
the blastocyst stage and maturing by E3.5 (Figure 2D). Although a 
deficit in blastocysts cannot be excluded in contributing to S6K1–/– 
embryonic phenotype, the growth retardation arises at the time of, 
or immediately following, trophoblast differentiation and intra-
uterine implantation, strongly suggesting that it appears as a func-
tion of impaired extraembryonic tissue development.
Impaired placental development in S6K1–/– mice. As nutritional 
restriction is associated with impaired trophoblast development 
and mTORC1 appears to play a critical role in placental function 
(22, 31), we questioned whether the absence of S6K1 could affect 
placental development. The placenta is composed of 3 distinct 
extraembryonic tissues largely derived from the fetus: an outer 
trophoblast giant-cell sheath, a middle spongiotrophoblast layer, 
and the innermost labyrinth (32). The labyrinth contains cells of 
Figure 3. Abnormal placental development in S6K1–/– mice. (A) Reduced 
placental weight in S6K1-deficient mice from E11.5–E13.5 (n = 5–14 per 
genotype). (B–E) Placenta sections from WT and S6K1–/– embryos at E13.5. 
(B) Labyrinthine trophoblast (Lb) and spongiotrophoblast (Sp) layers by 
H&E staining; (C) Tpbp Sp-specific marker by ISH labelling. Note that the 
Sp layer is thinner in S6K1–/– placenta (right). (D) Reduced intermingling of 
maternal (containing enucleated erythrocytes, open arrows) and embryonic 
blood vessels (identified by nucleated erythrocytes, filled arrows) in the Lb 
layer of S6K1–/– placenta (right). (E) Anti-PECAM staining (brown) shows 
dilated fetal blood vessels, irregular in diameter in S6K1–/– placenta (right). 
Filled arrows indicate nucleated erythrocytes. Scale bars: 25 μm. In A, 
values in are given as mean ± SEM. *P < 0.05 vs. WT, unpaired t test.
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
2 7 4 0 jci.org   Volume 125   Number 7   July 2015
to the embryo proper (32). To initiate these studies, we derived 4 
independent S6K1–/– ES cell lines (see Methods), and were able to 
obtain fetuses from one of them. Using this line, we obtained E13.5 
S6K1–/– tetraploid rescue (S6K1–/– TR) embryos, which developed to 
a size larger than S6K1–/– embryos and even slightly larger than WT 
embryos. Both were cultured in vitro and transplanted in WT sur-
rogate mothers (Figure 4, A–D). The larger-sized tetraploid embryo 
is consistent with previous studies, showing that tetraploid embryo 
complementation leads to increased embryonic weight, a pheno-
type termed hybrid vigor (37). The genotype of each tissue was con-
firmed by Southern blot analysis (Figure 4E). These results support 
the hypothesis that it is the failure of the S6K1–/– trophoblasts to dif-
ferentiate properly, which leads to impaired placental development, 
ultimately triggering IUGR. Such a phenotype has been described 
defect in S6K1–/– mice was the cause of IUGR, resulting in impaired 
β cell function. To test this hypothesis, we took advantage of 
tetraploid embryo complementation (35), such that S6K1–/– embry-
onic stem cells (ES cells) were aggregated with tetraploid 2-cell–
stage WT embryos. This allows one to supply a WT placenta to 
ES cells during embryonic development (35). The extent to which 
tetraploid embryo complementation can salvage IUGR is under-
scored by the complete rescue of a homozygous mouse derived 
from ES cells of a lethal trophoblastic mutant (36). The ensuing 
embryos were then transplanted into foster CD1 mothers (35). In 
this model, WT tetraploid cells supply the extraembryonic placental 
trophoblasts and yolk sac endodermic cells but are excluded from 
the embryo, owing to their increased ploidy. In contrast, the diploid 
ES cells cannot develop into trophoblast tissues and are confined 
Figure 4. Tetraploid WT placenta rescues growth retardation but not β cell size in S6K1–/– embryos. (A–D) WT, S6K1–/–, and S6K1–/– TR placentas and 
embryos at E13.5: (A) pictures representative of sizes; (B) histology by H&E staining: S6K1–/– TR placenta reveals correct intermingling of maternal (open 
arrows) and embryonic blood vessels (filled arrows) in labyrinthine trophoblast (Lb); (C) Body weights (n = 3–9 per genotype). (D) Placenta weights (n = 3–9 
per genotype). (E) Genotype of the tetraploid placenta and the ES cell–derived embryo from an S6K1–/– TR mouse by Southern blot analysis. The lanes were 
run on the same gel but were noncontiguous. (F and G) Pancreas sections from E16.5 WT and S6K1–/– TR embryos: (F) histology by H&E staining; (G) glu-
cose transporter GLUT2 by immunofluorescence (IF) staining; and (H) insulin (red) and glucagon (green) by IF staining. (I) Diminished β cell size in S6K1–/– 
TR pancreata, calculated on 56 determinations from WT embryos and 43 from S6K1–/– TR embryos (n = 3 per genotype). (J) β cell number in embryonic pan-
creata (n = 3 for per genotype, 18 sections per genotype). (K) Reduced insulin content in E16.5 S6K1–/– TR embryos (n = 3, from independent experiments) 
compared with WT embryos (n = 6) developed in surrogate mother mice. Scale bars: 25 μm. In C–K, values are given as mean ± SEM. *P < 0.05;  
**P < 0.01 vs. WT, unpaired t test.
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in mouse KOs of other protein kinases (38). Consistent with the 
rescue being dependent on proper placental development, the pla-
centas from E13.5 S6K1–/– TR embryos, unlike the S6K1–/– placentas, 
displayed typical WT structures with proper intermingling of blood 
vessels (Figure 4B), as well as normal weights (Figure 4D). These 
results indicate that the IUGR displayed by S6K1–/– embryos results 
from impaired placental development. To determine the impact of 
a WT placenta on S6K1–/– β cell development, we analyzed S6K1–/– 
TR embryos at E16.5. Unexpectedly, the results of H&E staining 
showed that the nuclei were still densely packed in the pan-
creas from S6K1–/– TR embryos, as compared with those from 
WT embryos (Figure 4F). These findings are consistent with 
the apparently smaller β cell size revealed by GLUT2 trans-
porter immunostaining (Figure 4G). Morphometric analysis 
of tissue sections costained with insulin and glucagon (Figure 
4H) confirmed that the WT tetraploid placenta did not res-
cue the reduction in β cell size (Figure 4I). The cell number 
also appeared to be slightly reduced in S6K1–/– TR versus WT 
embryos, though the difference was not significant (Fig-
ure 4J). Compatible with the reduction in β cell size, insulin 
content was still strongly reduced in S6K1–/– TR versus WT 
embryos (Figure 4K). Thus, the apparent reversion of the 
IUGR deficit in the tetraploid rescue, as determined by the 
restoration of a normal placenta phenotype (Figure 4B), does 
not appear to rescue the β cell size deficit (Figure 4, F–I). The 
placenta derived from WT trophoblasts also appears to rescue 
S6K1–/– TR β cell number, but surprisingly not β cell size, sug-
gesting an independent role for S6K1 in β cell growth.
S6K1 affect intrinsically embryonic β cell size. Given the 
ability of tetraploid embryos to completely rescue placen-
tal development of ES cells of a lethal trophoblast mutant 
(36), it would imply that loss-of-S6K1 effects on embryonic 
β cell size are independent of IUGR. If this is the case, it 
raises the possibility that S6K1 controls this response in 
a cell-autonomous manner. We have previously demon-
strated that Drosophila dS6K plays an intrinsic role in con-
trolling cell size in specific tissues, including the wing and 
the eye (30, 39), which we also found later to be the case 
in mouse embryonic fibroblasts (MEFs) (40). Moreover, 
others have shown that targeted β cell expression of a con-
stitutively active S6K1 cDNA leads to an increase in β cell 
size (16). To test this possibility, we first generated a trans-
genic mouse line expressing a myc-epitope–tagged S6K1 
cDNA driven by the rat insulin II promoter (RIP, RIP-S6K1) 
(41). By breeding WT Tg(RIP-S6K1) with S6K1–/– mice, we 
obtained S6K1–/– Tg(RIP-S6K1) mice. Although we could 
not detect the myc-epitope tag by immunofluorescence, 
we could detect S6K1, which was coexpressed with insulin 
in S6K1–/– Tg(RIP-S6K1) β cells of E16.5 embryos, but not 
in those of S6K1–/– E16.5 embryos (Supplemental Figure 
3). Reexpression of the RIP-S6K1 transgene in β cells did 
not rescue fetal weight (Supplemental Figure 4), whereas, 
in striking contrast to S6K1–/– β cells of E16.5 embryos, β 
cells of E16.5 S6K1–/– Tg(RIP-S6K1) embryos were equiva-
lent in size to those derived from E16.5 WT Tg(RIP-S6K1) 
embryos, as assessed by either H&E or GLUT2 staining 
(Figure 5, A and B, respectively). Moreover, even though 
staining with cleaved caspase-3 revealed increased apoptosis in β 
cells of S6K1–/– Tg(RIP-S6K1) versus WT Tg(RIP-S6K1) embryos, 
apoptosis occurred mainly outside of embryonic β cells (Figure 
5C). Morphometric analysis of insulin and glucagon costaining 
of tissue sections (Figure 5D) showed that the RIP-S6K1 trans-
gene was sufficient to rescue β cell number and size in E16.5 
S6K1–/– embryos (Figure 5, E and F, respectively). The rescue of 
β cell number and size by RIP-S6K1 transgenic expression was 
paralleled by a restoration in β cell insulin content (Figure 5G). 
Figure 5. Pancreatic β cell–specific expression of S6K1 restores diminished β cell 
size and insulin content in S6K1–/– embryos. (A–D) Pancreas sections from WT 
Tg(RIP-S6K1), S6K1–/–, and S6K1–/– Tg(RIP-S6K1) embryos at E16.5: (A) histology 
by H&E staining; (B) GLUT2 by immunofluorescence (IF) staining; (C) cleaved 
caspase-3 (red), insulin (green), and DAPI (blue), by IF; and (D) insulin (red) and 
glucagon (green), by IF staining. (E) β cell number in pancreas. A total of 18 sec-
tions from the middle of the pancreas was analyzed (n=3 for per genotype from 
3 independent crosses). (F) β cell size, obtained from 29–51 determinations (n = 3 
for per genotype). (G) Insulin content from embryonic pancreata (n = 3–10 for per 
genotype). Scale bars: 25 μm. Values in E–G are given as mean ± SEM. *P < 0.05, 
**P < 0.01 vs. other genotypes, ANOVA.
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
2 7 4 2 jci.org   Volume 125   Number 7   July 2015
These studies strongly support the hypothesis that the reduction 
in β cell number and size explains the reduction in insulin con-
tent in S6K1–/– embryos (Figures 1 and 5).
RIP-S6K1 transgene expression improves glucose tolerance. West-
ern blot analysis of adult 3- to 5-month-old mice revealed that 
the expression of the Myc-epitope-tagged S6K1 was maintained 
in both WT Tg(RIP-S6K1) and S6K1–/– Tg(RIP-S6K1) mice (Figure 
6A). Following birth, reexpression of the RIP-S6K1 transgene in 
S6K1–/– mice did not rescue the reduction in body size, nor were 
there any obvious alterations in the body composition in terms of 
either fat mass or lean mass, when compared with S6K1–/– mice 
(Figure 6, B–D). Likewise RIP-S6K1 transgene expression had lit-
tle effect on whole-body energy expenditure (EE) when compared 
with S6K1–/– mice (Figure 6E). In contrast to these observations, 
RIP-S6K1 transgene expression in β cells restored circulating insu-
lin in S6K1–/– mice to levels similar to those observed in either WT 
Tg(RIP-S6K1) or WT mice (Figure 6F). Previously, we had shown 
that S6K1–/– mice are mildly glucose intolerant, which we attributed 
to their hypoinsulinemia (14). However, despite hypoinsulinemia, 
such mice maintain glucose homeostasis and insulin sensitivity 
(9), apparently due to both reduced insulin levels and adiposity, as 
well as the loss of the negative feedback loop from S6K1 to IRS1 in 
muscle and adipose (14). Consistent with these findings, RIP-S6K1 
transgene expression in S6K1–/– mice not only rescued the mild 
glucose intolerance, but dramatically enhanced this response over 
that of WT RIP-S6K1 or WT mice (Figure 6G). It should be noted 
that the expression of S6K1 in β cells, but not its levels of expression 
(Figure 6A), correlated with the restoration of circulating insulin 
levels (Figure 6F), suggesting that a threshold of S6K1 activity may 
be critical for this response (see below). Importantly, increased 
insulin levels in S6K1–/– Tg(RIP-S6K1) mice neither affected their 
adiposity nor their insulin sensitivity (Figure 6, C and H, respec-
tively). Therefore the increase in glucose tolerance displayed by 
S6K1–/– Tg(RIP-S6K1) mice, as compared with S6K1–/– mice, appears 
to be due to restoration of normal circulating levels of insulin.
RIP-S6K1 transgene expression restores β cell size and S6 phospho-
rylation. Consistent with the restoration of normal insulin levels, 
H&E and insulin staining of adult islets showed a clear increase in 
β cell size of S6K1–/– Tg(RIP-S6K1) mice (Figure 7, A and B), which 
was confirmed by morphometric analysis of insulin-stained cells 
Figure 6. Pancreatic β cell–specific expression of S6K1 improves glucose tolerance. (A) RIP-S6K1 transgene expression in islet extracts by Western blot 
analysis detecting Myc-tag and S6K1 protein. (B) Body weight was measured in 8-month-old male mice (n = 6–12 per genotype). (C–H) Male mice were 
analyzed at 3–6 months of age for (C) percent of fat-mass and (D) lean mass. They were normalized by body weight and determined by NMR analysis  
(n = 5–9 mice of per genotype); (E) increased oxygen consumption in S6K1 transgenic mice measured either during the day or night as indicated (n = 4–9 
mice per genotype). (F) Plasma insulin concentrations in mice fasted for 6 hours (n = 6–10 mice of per genotype; experiments were performed twice). (G) 
Blood glucose concentrations before and after i.p. injection of 2 g d-glucose per kg body weight in mice fasted overnight (n = 5–9 mice per genotype). (H) 
Insulin tolerance test after 3 hours fasting: plasma glucose concentration before and after intraperitoneal injection of insulin (0.75 U per kg body weight;  
n = 5–9 mice per genotype). Values in B–H are given as mean ± SEM. *P < 0.05 vs. other genotypes, **P < 0.01 vs. other genotypes, ANOVA.
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Discussion
Given the potential role of S6K1 inhibitors in the treatment of 
T2DM, we set out to determine whether the effects on β cell size 
and hypoinsulinemia observed in S6K1–/– mice were due to IUGR 
or were mediated by an intrinsic β cell defect. The results demon-
strate that S6K1 deficiency leads to IUGR, but independently 
affects β cell size, in a cell-autonomous manner. Although it is 
generally accepted that a deficiency in the placental nutrient sup-
ply leads to IUGR and subsequent lesions in β cell development 
(18), others have recently reported in an ovine model of IUGR that 
following midgestation, the stage at which IUGR is diagnosed in 
humans, there is already a decrease in β cell proliferation and fetal 
insulin levels (25). From these observations, they hypothesize that 
impaired β cell development and decreased insulin levels may be 
a cause rather than an effect of IUGR (25). Nevertheless, the RPS6 
knockin mice, harboring serine to alanine substitutions in the 5 
RPS6 phosphorylation sites, are apparently of normal size at birth, 
despite hypoinsulinemia and reduced β cell size (46). In agree-
ment with the latter finding, we show that when S6K1–/– embryos 
develop with tetraploid WT placentas, IUGR is rescued, but β cell 
growth and function remain impaired (Figure 4). However, in con-
trast to the RPS6 knockin mice, our results also suggest that loss of 
S6K1 activity independently induces IUGR. We show that IUGR 
can be detected at E9.5 in S6K1–/– mice (Figure 2) long before the 
onset of β cell growth defects at E16.5, when insulin-producing 
pancreatic islets start forming. Moreover, when S6K1 is reintro-
duced in the β cells of S6K1–/– mice, there is no impact on IUGR, 
despite the correction in β cell size and insulin levels (Figures 5–7). 
(Figure 7C), as well as by a significant increase in total endocrine 
mass (Figure 7D), although it did not reach that of WT mice. The 
RIP promoter has been reported to be expressed in the hypothal-
amus (42), and recent studies have shown that hypothalamus can 
control insulin secretion by β cells (43). However, we did not detect 
expression of S6K1 in hypothalamus in S6K1–/– Tg(RIP-S6K1) mice, 
potentially due to the genomic integration site or an epigenetic 
modification of the transgene (Supplemental Figure 5). Moreover, 
despite the known effects of S6K1 in the negative feedback loops 
to suppress both protein kinase B (PKB, also known as AKT) (9) 
and ERK (44), neither PKB S473 nor ERK T202/Y204 phospho-
rylation appeared to be affected by loss of S6K1 or its reexpression 
in S6K1–/– Tg(RIP-S6K1) mice (Figure 7E). It may be that the role of 
the feedback loop can only be observed under conditions of nutri-
ent overload, as we found for PKB (9). Finally, it has been reported 
that mice harboring a knockin of 40S RPS6 cDNA, where the 5 
serine RPS6 phosphorylation sites (45) are substituted by alanines, 
display hypoinsulinemia and experience β cell size reduction (46). 
This finding led to the suggestion that the size reduction observed 
in the β cells of S6K1–/– mice (14) is due to a decrease in RPS6 phos-
phorylation (46). Consistent with this observation, in islets from 
S6K1–/– mice, S6K1 phosphorylation is absent and S6 phosphory-
lation is severely reduced. However, in islets from S6K1–/– Tg(RIP-
S6K1) mice, S6K1 T389 and S6 S240/S244 phosphorylation are 
both restored to levels similar to those observed in WT mice 
(Figure 7E). Taken together, the results suggest that the effects of 
S6K1 on pancreatic β cell size may be mediated, at least in part, by 
increased S6 phosphorylation.
Figure 7. Pancreatic β cell–specific expression 
of S6K1 restores diminished β cell size and S6 
phosphorylation in adult S6K1–/– mice. (A and B) 
Pancreas tissue sections from adult mice at 3–6 
months of age: (A) histology, by H&E staining; 
(B) β cell size in islets, by Hoechst staining for 
DNA (blue) and immunofluorescence (IF) staining 
for insulin (red). (C) β cell density in islets was 
assessed by counting the number of nuclei nor-
malized for islet area (n = 32–42 islets in 3–5 mice 
per genotype). (D) Endocrine mass calculated from 
13–24 determinations (n = 3–5 mice per genotype). 
(E) Phosphorylated S6K1 T389 (pS6K1 T389), 
phosphorylated S6 S240/S244 (pS6 S240/S244), 
phosphorylated Akt (pAkt S473), and phosphory-
lated ERK 1 and 2 T202/Y204 (pERK T202/Y204) 
by Western blots analyses. Scale bars: 50 μm. 
Values in C and D are given as mean ± SEM.  
*P < 0.05 vs. other genotypes, ANOVA.
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S6K1-deficient mice remained insulin sensitive, as they did on a 
normal chow diet (9, 14). Here we show that reexpression of S6K1 
in the β cells of S6K1–/– Tg(RIP-S6K1) mice dramatically enhances 
glucose tolerance over that of WT mice (Figure 6G) by restoring 
normal plasma insulin levels (Figure 6F) under conditions where 
reduced adiposity (Figure 6C) and increased insulin sensitivity 
displayed by S6K1–/– mice are maintained (Figure 6H). The obser-
vation that rapamycin does not have an inhibitory effect on acute 
insulin secretion (54) but can rapidly increase insulin sensitivity in 
obese rats (55) initially raised the possibility of employing the drug 
as an insulin sensitizer. However, chronic treatment of posttrans-
plant patients with rapamycin has been associated with impaired 
glucose tolerance and T2DM (56), due in part to β cell toxicity (57). 
Unlike in the case of S6K1 deletion, we observe a similar pheno-
type in mice where we have conditionally deleted the Mtor gene 
in β cells (J. Park, S.H. Um, and S.C. Kozma, unpublished obser-
vations). Moreover, others have provided evidence that insulin 
resistance caused by chronic treatment of mice with rapamycin is 
due to disruption of mTORC2 and not inhibition of mTORC1 (58). 
Thus the more deleterious effects of rapamycin could be attrib-
uted to the inhibition of multiple mTORC1 substrates, in addition 
to S6K1 (57), and its ability to inhibit mTORC2 (58). This argument 
is consistent with preliminary studies showing that in cell culture, 
compared with depletion of S6K1, rapamycin treatment leads to 
a more profound and lasting inhibition of the negative feedback 
loop to IRS1/2, as measured by insulin stimulation of PKB (K. 
Masuda and G. Thomas, unpublished observation). These find-
ings, and the mild glucose intolerance displayed by S6K1–/– mice, 
raise the possibility that a selective inhibitor of S6K1 may have a 
clinical window of efficacy as an insulin sensitizer, beyond that of 
mTORC1 and mTORC2 inhibition.
Methods
Mice. S6K1–/– mice on C57BL/6J background (9) were obtained from 
heterozygous or homozygous parental crosses, as indicated for the 
different methods. Genotyping was performed on tail DNA — or DNA 
derived from dissected embryos and placentas, in the case of tetraploid 
embryo complementation studies — by Southern blot analysis or PCR. 
The PCR primers corresponded to: S6K1 forward, 5′-GTAGGGCACT-
TAAATGACCAC-3′; S6K1 reverse, 5′-TGTCCCTATTAAT-GCT-
CAAGG-3′; neo reverse, 5′-GCCTTCTTGA CGAGTTCTTCTGAG-3′.
Histological analysis. WT, S6K1+/–, and S6K1–/– mouse embryos 
and placentas were collected and fixed in 10% formalin overnight at 
4°C. Fixed samples were embedded in paraffin, and 5-μm sections 
were cut and mounted on slides to generate a series of 6 slides with 
comparable adjacent sections. The average number of slides collected 
were 90–100 from pancreata per genotype using 3 heterozygous and 
4 homozygous mouse matings. For morphological analyses, slides of 
each series were H&E stained. For immunofluorescence, sections of 
embryonic and adult pancreata were stained with rabbit anti-gluca-
gon (1:50, Invitrogen), guinea pig anti-insulin (1:400, Millipore), and 
rabbit anti-Glut2 (1:200, provided by B. Thorens) antisera. Detection 
was performed using Alexa Fluor 488 and 594 (Invitrogen). Morpho-
metric analyses and cell counting were done using ImagePro Plus 
software (Media Cybernetics). Insulin and glucagon staining was per-
formed using 15–16 slides per pancreas, representing 1/6 of the organ. 
Forty-five to 52 slides were analyzed per genotype. To calculate the 
It should be noted that in the mouse, deletion of Mtor — the S6K1 
T389 kinase — abrogates development at E5.5, as it is required for 
trophoblast differentiation, outgrowth, and invasion of the uter-
ine stroma during placental development (22, 31, 47). Deletion of 
S6K1 may have less damaging developmental effects because it 
represents only one of the multiple downstream targets of mTOR. 
Taken together, these findings support the possibility that nutri-
ent deprivation during early development may use independent 
routes to affect IUGR and impair β cell function.
mTORC1 plays a key role in the activation of S6K1 by provid-
ing a docking site for phosphoinositide-dependent protein kinase 
(PDK1), the T229 S6K1–activation loop kinase (48). Previous stud-
ies have shown that mice or embryos lacking PDK1 exhibit both 
reduced β cell number and size (49, 50). PDK1 also serves as the 
S308 PKB–activation loop kinase. As PKB mediates the canonical 
PI3K signaling pathway to mTORC1, this suggests that PDK1 plays 
a key role in 2 distinct pathways leading to S6K1 activation: one 
through nutrients and the other through hormone-mediated PKB 
activation. The effect on cell number, but not cell size, observed 
in PDK1-deficient β cells is largely rescued by crossing the PDK1- 
deficient mice with mice haploinsufficient for FoxO1, whose 
activity is negatively regulated by PKB phosphorylation (49). In 
line with this finding, mice lacking rictor, an essential component 
of the mTORC2 required for PKB-S473 phosphorylation, exhibit 
reduced β cell number and increased FoxO1 activity (51). These 
observations led to the hypothesis that the effects of PDK1 defi-
ciency on cell number are regulated through suppression of PKB, 
whereas those on cell size are regulated by S6K1 (49). Consis-
tent with the effects of S6K1 on β cell size, TSC1/TSC2 and Rheb 
(52) — upstream effectors of mTORC1/S6K1 — have been impli-
cated in this response, and ectopic expression of a constitutively 
active S6K1 transgene in β cells results in increased β cell size (16). 
Genetic studies in mice suggest that the size reduction observed in 
the β cells of S6K1–/– mice is mediated by a decrease in RPS6 phos-
phorylation (46), which has been implicated in the recruitment of 
mRNAs to the cap-binding complex translation initiation complex 
(53). Nevertheless, it should be noted that the effects of the loss of 
RPS6 phosphorylation on β cell size are based on a whole-animal 
replacement with the multiple-alanine site RPS6 mutant, such 
that the effects on β cell size may not be cell autonomous. At this 
stage, it would be informative to determine whether the effects of 
S6K1 on β cell size are meditated through RPS6 by generating a β 
cell–specific knockin of the RPS6 alanine allele.
Earlier studies from this laboratory showed that S6K1-deficient 
mice exhibit mild glucose intolerance, which was attributed to 
reduced β cell size, leading to decreased glucose-stimulated insu-
lin secretion (14). From the studies described here, the reduction 
in β cell size does not appear to be mediated through either PKB or 
ERK, but most likely through reduced RPS6 phosphorylation (Fig-
ure 7E). We initially attributed the mild effect on glucose intoler-
ance to the fact that S6K1-deficient mice were still able to increase 
circulating insulin levels in answer to a glucose challenge, albeit 
less robustly (5). However, our later studies revealed that the abil-
ity of S6K1-deficient mice to maintain glucose homeostasis could 
also be explained, in part, by increased insulin sensitivity (9, 14). 
This effect was particularly evident when mice were challenged 
with an HFD (9, 14). WT mice became insulin resistant, whereas 
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
2 7 4 5jci.org   Volume 125   Number 7   July 2015
Scanning electron microscopic analysis. Following homozygous 
mouse mating, embryos were fixed in 1.25% glutaraldehyde, 1% para-
formaldehyde in 0.08 M cacodylate buffer containing 0.02% CaCl2 
for 1 hour at room temperature, then overnight at 4°C. They were post-
fixed in 1% OSO4 in water, washed, and dehydrated by alcohol. Scan-
ning electron microscopic analysis was performed as described (9).
Establishment of S6K1–/– ES cells. S6K1–/– embryos, obtained from 
homozygous parental crosses, were flushed at the morula stage and 
incubated overnight in M16 medium. On the next day, blastocysts 
were transferred to 6-cm dishes coated with inactivated mouse fibro-
blasts and 5637 cells (ATCC HTB9) to facilitate ES cell development. 
A few days later, the inner cell masses (ICMs) were collected with a 
glass pipette, treated with trypsin (Invitrogen) for 10 minutes at RT, 
and further propagated on inactivated fibroblasts. The medium used 
throughout the process was KO-DMEM supplemented with pen/strep/
glutamine, gentamycin (Invitrogen), β-mercaptoethanol (Sigma- 
Aldrich), LIF (Novartis), and 15% FBS (PAN-Biotech GmbH).
Aggregation of tetraploid WT embryos with diploid S6K1–/– ES cells. 
WT embryos were recovered at the 2-cell stage (E1.5). The blastom-
eres were fused by electrofusion (60), and the resulting tetraploid 
embryos were cultured for 48 hours at 37°C, 5% CO2, and 100% 
humidity in M16 medium (60). Next, the zona pellucida was removed 
from the 4-cell–stage tetraploid embryos by Tyrode’s Acid treatment 
and further cultured in microdrops (60). Three independent S6K1–/– 
ES cell clones were brought to single-cell suspension by a 5-minute 
trypsin treatment (Invitrogen). The S6K1–/– ES cell suspensions were 
left to reaggregate into small clumps of 10–15 ES cells and placed in 
separate wells containing 2 tetraploid embryos, as described (60). 
The next day, blastocyst-stage embryos were harvested from the wells 
and implanted into the uteri of E2.5 pseudopregnant-recipient CD1 
outbred female mice. This technique allows for the development of 
embryos in utero; however, it generates less than 5% living birth, and 
mice die within hours after birth (37). Therefore, analyses were per-
formed at E13.5 and E16.5.
Generation of transgenic mice expressing S6K1 in pancreatic β cells. 
The RIP-S6K1 DNA construct consisted of a 720-bp fragment of 
RIP driving transcription of a myc-S6K1 cDNA. RIP-S6K1 DNA was 
injected into B6CF2 — second-generation (F2) obtained from the 
crosses between C57Bl/6J and BALB/C mice — fertilized eggs. Found-
ers were identified by PCR analysis, and germline transmission was 
confirmed by Southern blot analysis. Genotyping was performed by 
PCR using primers derived from RIP and S6K1 cDNA sequences as 
follows: Forward, 5′-CAGGCCACCCAGGAGCCCC-3′; reverse 1, 
5′-GCATGATGTTCTC CGGCTTC AGG-3′; reverse 2, 5′-GTAAAT-
GCCCC-AAAGCCATGGAG-3′. The transgenic mice were back-
crossed for 6 generations on C57BL/6 background prior to breeding 
with S6K1–/– mice. Isolated islets were obtained from adult WT Tg(RIP-
S6K1) and S6K1–/– Tg(RIP-S6K1) mice by collagenase P digestion (14). 
The lysates were analyzed by Western blotting with antibodies against 
S6K1 (Santa Cruz Biotechnology Inc.) and c-Myc (Upstate Biotechnol-
ogy Inc.). Two of 15 S6K1–/– Tg(RIP-S6K1) mouse lines were positive 
for S6K1 expression, and one of them could be maintained for experi-
mentation. The hypothalamus was dissected from 3–6 mice per estab-
lished genotypes to assess S6K1 expression.
Metabolic phenotyping. Indirect calorimetry, locomotor activity, 
metabolic performance, and home-cage activity were studied by 
using a combined indirect calorimetry system (TSE Systems GmbH). 
mean size of individual α and β cells, a defined area was divided by the 
number of cell nuclei positive for either insulin or glucagon, as previ-
ously described (14). Apoptosis was determined in pancreatic sections 
stained for insulin (guinea pig anti-swine insulin, 1:800, Dako) and 
cleaved caspase-3 (rabbit anti-cleaved caspase-3, 1:50, Cell Signal-
ing Technology) as described (52). Apoptotic cells were identified by 
costaining for insulin and cleaved caspase-3. Three sections per pan-
creas were examined, and at least 50–100 insulin-stained cells were 
counted for each animal. IHC and ISH were performed using placental 
tissue sections from the middle of each placenta. For anti–PECAM-1 
staining, the sections were incubated with 0.1% trypsin after rehydra-
tion for 12 minutes at 37°C, followed by 20 minutes incubation with 
2N HCl. Sections were then incubated overnight at 4°C with rat mono-
clonal anti–PECAM-1 (1:50, Pharmingen). Biotinylated horse anti-rat 
(Vector Laboratories) was used as the secondary antibody, followed by 
incubation with the ABC reagent (Vector Laboratories), detection with 
DAB (Vector Laboratories), and nuclear counterstaining with hema-
toxylin. The endocrine mass was quantified using the following equa-
tion: β cell mass = pancreas weight (mg) × relative insulin surface (total 
islet area μm2/total pancreas area μm2) × 100.
ISH analysis. The trophoblast-specific protein α (Tpbp/-4311) gene 
was used as a molecular marker of spongiotrophoblast cells (59). Pla-
centa sections of WT, S6K1+/–, and S6K1–/– embryos, from both hete-
rozygous or homozygous matings, were rehydrated and permeabilized 
using 20 μg/ml proteinase K in 10 mM Tris pH8/20 mM EDTA for 15 
minutes at room temperature, fixed in 4% paraformaldehyde/0.2% 
glutaraldehyde, and dehydrated in a graded methanol series. Anti-
sense and sense riboprobes were generated by in vitro transcription 
using the DIG RNA Labeling Kit (Roche Diagnostics) following the 
manufacturer’s instruction. NBT (Nitroblue tetrazolium chloride) and 
BCIP (5-Bromo-4-chloro-3-indoyl-phosphate, 4-toluidine salt), both 
from Roche Diagnostics, were used as the substrate for visualization.
Insulin content in blood and embryonic pancreata. Blood samples 
from adult mice issued from both heterozygous and homozygous mat-
ings were collected and centrifuged. Embryonic pancreata from each 
genotype obtained from both heterozygous and homozygous matings 
were placed into PBS and then sonicated 3 times for 10 seconds each 
time. Insulin concentration in the plasma or in pancreas extracts was 
measured using the ultrasensitive insulin ELISA kit (Crystal Chem 
Inc.) or by radioimmunoassay (Millipore), respectively.
Embryonic growth analysis. For embryo staging, the day of vaginal 
plug appearance was considered E0.5. Embryos were obtained from 4 
heterozygous and 26–32 homozygous crosses for WT and S6K1–/– mice, 
respectively. For developmental analyses of growth, embryos and pla-
centas were dissected from pregnant mice, patted dry, and weighed 
on a microbalance. For embryos obtained from heterozygous parental 
crosses, samples were collected and genotyped.
Preimplantation development in vitro. Following superovulation and 
mating of homozygous female mice with homozygous male mice, E1.5 or 
E3.5 embryos were collected and individually cultured in M16 medium, 
as described (60). The morphology of the embryos was recorded.
Skeletal staining. Embryos were eviscerated, skinned, fixed in 
ethanol, and stained with alcian blue 8GS (cartilaginous elements) 
and alizarin red S (mineralized elements) for 3–5 days. The tissues 
were cleared with 1% KOH, and the skeletons were stored in glyc-
erol. Embryos were obtained from 3 heterozygous and 4 homozygous 
crosses per genotype.
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Volumes of oxygen consumed (VO2, ml/kg/h) and carbon dioxide 
produced (VCO2, ml/kg/h) were measured continuously and simul-
taneously every 45 minutes to determine the respiratory quotient 
(RQ; VCO2/VO2) and to calculate EE (kcal/kg/h, EE = 3.815×10-3 × 
VO2 + 1.232 × 10-3 × V CO2). During the 95 hours of measurements, 
the animals remained unconstrained except for a single filling of 
both water bottles and food hoppers. Prior to the experiment, all 
mice were allowed to acclimatize to the air-tight cages for 22 hours.
Body composition analysis. Whole-body composition (fat and lean 
mass) was measured using NMR technology (EchoMRI).
Statistics. Data are presented as mean ± SEM. The main and inter-
active effects were analyzed by ANOVA factorial or repeated measure-
ments, or by 1-way ANOVA. Differences between individual group 
means were analyzed by a post-hoc Bonferroni test or 2-tailed unpaired 
t test. Analyses were performed using GraphPad Prism software. Dif-
ferences were considered to be statistically significant at P < 0.05.
Study approval. Animal care and study protocols were approved by 
the Institutional Animal Care and Use Committee of Sungkyunkwan 
University School of Medicine and the Animal care committee of the 
University of Cincinnati, and were in accordance with NIH guidelines.
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